Table 2.

Randomized Clinical Trials and Extension Studies of THC:CBD Oromucosal Spray (Nabiximols) in Neuropathic Pain

Reference	Neuropathic Pain Study	Randomized/Entered Extension Study, n	Completed, n	Treatment Duration	Change in Pain 0–10 NRS for THC:CBD Oromucosal Spray (Nabiximols) vs Placebo	p-value
[87]	Multiple sclerosis	66	64	4 weeks	–2.7 vs –1.4 (Δ 1.3)	0.005
[88]	Multiple sclerosis (open-label extension of87	63	34 (1 year) 28 (2 years)	2 years	–2.9†	N/A
[89]	Multiple sclerosis	339	297	14 weeks	–1.93 vs –1.76 (Δ 0.17)	0.47
[90]	Multiple sclerosis or other defects of neurological function	70	63	3 weeks	–1.3 vs –0.9 (Δ 0.4)§	0.33
[92]	Spinal cord injury	116	106	3 weeks	–0.74 vs –0.69 (∆ 0.05)	0.71
[93]	Brachial plexus avulsion	48	45	2 weeks	Δ –0.58 vs placebo§	0.005
[94]	Allodynia	125	105	5 weeks	–1.48 vs –0.52 (Δ 0.97)	0.004
[95]	Allodynia	246	173	14 weeks	Δ –0.34 vs placebo	0.139
[96]	Diabetes	297	230	14 weeks	–1.67 vs –1.55 (∆ 0.12)	0.63
[97]	Allodynia or diabetes (open-label extension of95,96	380 (176 allodynia, 204 diabetes)	234 (100 allodynia, 134 diabetes)	38 weeks	–2.7 vs baseline‡	N/A
[98]	Chemotherapy-induced	18	16	6 weeks	–1.25 vs –0.44 (Δ 0.81)	0.29

Notes: ^†Mean pain 0–10 NRS score in patients completing 2 years’ follow-up; ^§0–10 Box Scale score; ^‡Pain 0–10 NRS score decreased over time from a mean of 6.9 points (baseline in the parent studies) to a mean of 5.5 points (end of parent studies), to a mean of 4.2 points (end of open-label treatment) in remaining patients.

Abbreviation: NRS, numerical rating scale.